Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS

David S Perlin, Inbal Zafir-Lavie, Lori Roadcap, Shane Raines, Carl F Ware, Garry A Neil, David S Perlin, Inbal Zafir-Lavie, Lori Roadcap, Shane Raines, Carl F Ware, Garry A Neil

Abstract

Many coronavirus disease 2019 (COVID-19) patients demonstrate lethal respiratory complications caused by cytokine release syndrome (CRS). Multiple cytokines have been implicated in CRS, but levels of tumor necrosis factor superfamily 14 (TNFSF14) (LIGHT) have not been previously measured in this setting. In this study, we observed significantly elevated serum LIGHT levels in hospitalized COVID-19 patients compared to healthy age- and gender-matched control patients. The assay detected bioavailable LIGHT unbound to the inhibitor Decoy receptor-3 (DcR3). Bioavailable LIGHT levels were elevated in patients both on and off ventilatory support, with a trend toward higher levels in patients requiring mechanical ventilation. In hospitalized patients over the age of 60, who exhibited a mortality rate of 82%, LIGHT levels were significantly higher (P = 0.0209) in those who died than in survivors. As previously reported, interleukin 6 (IL-6) levels were also elevated in these patients, with significantly (P = 0.0076) higher levels observed in patients who died than in survivors, paralleling the LIGHT levels. Although attempts to block IL-6 binding to its receptor have shown limited success in COVID-19 CRS, neutralization of LIGHT may prove to be more effective owing to its more central role in regulating antiviral immune responses. The findings presented here demonstrate that LIGHT is a cytokine which may play an important role in COVID-19 patients presenting with acute respiratory distress syndrome (ARDS) and CRS and suggest that LIGHT neutralization may be beneficial to COVID-19 patients.

Trial registration: ClinicalTrials.gov NCT04412057.

Keywords: ARDS; COVID-19; IL-6; LIGHT; MAb; TNFSF14; cytokine storm.

Copyright © 2020 Perlin et al.

Figures

FIG 1
FIG 1
IL-6 and free LIGHT levels in serum of COVID-19 patients. (A) Free LIGHT serum levels in ventilated (n = 27) and nonventilated (n = 20) COVID-19 patients compared to healthy controls (n = 30). (B) Free LIGHT serum levels in COVID-19 patients who were 60 years of age or older, grouped by clinical outcome (recovered versus deceased). (C) IL-6 serum levels in ventilated (n = 27) and nonventilated (n =20) COVID-19 patients compared to healthy controls (n = 30). (D) IL-6 serum levels in COVID-19 patients who were 60 years of age or older, grouped by clinical outcome (recovered versus deceased). IL-6 levels were measured using a validated immunoassay and a Luminex platform. Free LIGHT levels were measured using a validated immunoassay and a Quanterix ultra-high-sensitivity SIMOA platform. P values were calculated using the Kruskal-Wallis test.

References

    1. Yang M. 2020. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN .
    1. Pedersen SF, Ho YC. 2020. SARS-CoV-2: a storm is raging. J Clin Invest 130:2202–2205. doi:10.1172/JCI137647.
    1. Moore JB, June CH. 2020. Cytokine release syndrome in severe COVID-19. Science 368:473–474. doi:10.1126/science.abb8925.
    1. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, Zhu H, Hu K, Liu J, Liu Z, Wang S, Gong Y, Zhou C, Zhu T, Cheng Y, Liu Z, Deng H, Tao F, Ren Y, Cheng B, Gao L, Wu X, Yu L, Huang Z, Mao Z, Song Q, Zhu B, Wang J. 2020. Clinical characteristics of 82 death cases with COVID-19. medRxiv 10.1101/2020.02.26.20028191.
    1. Zaim S, Chong JH, Sankaranarayanan V, Harky A. 2020. COVID-19 and multiorgan response. Curr Probl Cardiol 45:100618. doi:10.1016/j.cpcardiol.2020.100618.
    1. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, Fung KS, Tang HL, Yan WW, Chan HWH, Lai TST, Tong KL, Lai KN. 2005. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 67:698–705. doi:10.1111/j.1523-1755.2005.67130.x.
    1. Liu B, Li M, Zhou Z, Guan X, Xiang Y. 2020. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 111:102452. doi:10.1016/j.jaut.2020.102452.
    1. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu J-L, Xu W, Zhang Y, Lv F-J, Su K, Zhang F, Gong J, Wu B, Liu X-M, Li J-J, Qiu J-F, Chen J, Huang A-L. 2020. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med doi:10.1038/s41591-020-0965-6.
    1. Ward-Kavanagh LK, Lin WW, Šedý JR, Ware CF. 2016. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 44:1005–1019. doi:10.1016/j.immuni.2016.04.019.
    1. Mehta AK, Doherty T, Broide D, Croft M. 2018. Tumor necrosis factor family member LIGHT acts with IL-1β and TGF-β to promote airway remodeling during rhinovirus infection. Allergy 73:1415–1424. doi:10.1111/all.13390.
    1. Xu W, Xu Z, Huang L, Qin E-Q, Zhang J-L, Zhao P, Tu B, Shi L, Li W-G, Chen W-W. 2019. Transcriptome sequencing identifies novel immune response genes highly related to the severity of human adenovirus type 55 infection. Front Microbiol 10:130. doi:10.3389/fmicb.2019.00130.
    1. Croft M, Duan W, Choi H, Eun S-Y, Madireddi S, Mehta A. 2012. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 33:144–152. doi:10.1016/j.it.2011.10.004.
    1. da Silva Antunes R, Mehta AK, Madge L, Tocker J, Croft M. 2018. TNFSF14 (LIGHT) exhibits inflammatory activities in lung fibroblasts complementary to IL-13 and TGF-β. Front Immunol 9:576. doi:10.3389/fimmu.2018.00576.
    1. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuom G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carli F, Bedini A, Corradi L, Fantini R, Castaniere I, Girardis M, Tedeschi S, Giannella M, Bartoletti M, Pascale R, Dolci G, Brugioni L, Pietrangelo A, Cossarizza A, Pea F, Clini E, Calvarani C. 2020. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2:E474–E484. doi:10.1016/S2665-9913(20)30173-9.
    1. Desai P, Tahiliani V, Hutchinson TE, Dastmalchi F, Stanfield J, Abboud G, Thomas PG, Ware CF, Song J, Croft M, Salek-Ardakani S. 2018. The TNF superfamily molecule LIGHT promotes the generation of circulating and lung-resident memory CD8 T cells following an acute respiratory virus infection. J Immunol 200:2894–2904. doi:10.4049/jimmunol.1701499.
    1. Steinberg MW, Shui JW, Ware CF, Kronenberg M. 2009. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol 31:207–221. doi:10.1007/s00281-009-0157-4.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅